Back to top
more

Entera Bio (ENTX)

(Delayed Data from NSDQ)

$3.47 USD

3.47
428,423

+0.05 (1.46%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $3.48 +0.01 (0.29%) 6:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy

by Zacks Equity Research

ENTX posts positive PK data for its first oral GLP-2 therapy, signaling a potential breakthrough in short bowel syndrome treatment.

Zacks Equity Research

Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Entera Bio (ENTX) delivered earnings and revenue surprises of -60% and 5%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging Argenx (ARGX) This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year.

Zacks Equity Research

ENTX & OPK Stock May Gain Following Positive PK/PD Research Data

by Zacks Equity Research

Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.

Zacks Equity Research

Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Entera Bio Ltd. (ENTX) and argenex SE (ARGX) have performed compared to their sector so far this year.

Zacks Equity Research

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Entera Bio Ltd. (ENTX) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

Zacks Equity Research

All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy

by Zacks Equity Research

Entera Bio (ENTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU

by Zacks Equity Research

AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.

Zacks Equity Research

Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Entera Bio Ltd. (ENTX) and PetIQ (PETQ) have performed compared to their sector so far this year.

Zacks Equity Research

Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study

by Zacks Equity Research

Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.